Cutaneous melanoma in solid organ transplant patients

Giornale Italiano di Dermatologia e Venereologia

Volumn 149, Issue 4, 2014, Pages 389-394

  Russo, I ^a   Piaserico, S ^a   Belloni Fortina, A ^a   Alaibac, M ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Immunosuppression; Melanocytes; Nevi and melanomas; Organ transplantation

Indexed keywords

INTERLEUKIN 12; MEMBRANE ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE; STEROID; IMMUNOSUPPRESSIVE AGENT;

ARTICLE; CANCER PROGNOSIS; CARCINOGENESIS; CELL PROLIFERATION; CIRCULATING TUMOR CELL; CUTANEOUS MELANOMA; DENDRITIC CELL; DISEASE TRANSMISSION; DOWN REGULATION; GRAFT RECIPIENT; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPROMISED PATIENT; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MELANOCYTE; MELANOCYTIC NEVUS; METASTASIS POTENTIAL; MICROMETASTASIS; ORGAN DONOR; ORGAN TRANSPLANTATION; SKIN PIGMENTATION; STEROID THERAPY; SUN EXPOSURE; ITALY; MELANOMA; NEVUS, PIGMENTED; PROGNOSIS; RISK FACTOR; SKIN NEOPLASMS;

HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; ITALY; MELANOMA; NEVUS, PIGMENTED; ORGAN TRANSPLANTATION; PROGNOSIS; RISK FACTORS; SKIN NEOPLASMS; TRANSPLANT RECIPIENTS;

EID: 84913553838     PISSN: 03920488     EISSN: 18271820     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Zwald F, Brown M. Skin cancer in solid organ transplant recipients, advances in therapy and management, part I: epidemiology of skin cancer in solid organ transplant recipients. J Am Acad Dermatol 2011;65:253-61.
2. Kempf W, Mertz KD, Hofbauer GF, Tinguely M. Skin cancer in organ transplant recipients. Pathobiology 2013;80:302-9.
3. Duncan KO, Geisse JK, Leffel DJ. Epithelial precancerous lesions. In: Wolff K, Goldsmith LA, Gilchrest BA, Palier AS, Leffel DJ, editors. Fitzpatrick's dermatology in general medicine. 7th ed. New York: Mc Graw Hill; 2007. p. 1007-27.
4. Stockfleth E, Kerl H. Guidelines for the management of actinic keratoses. Eur J Dermatol 2006;16:599-606.
5. Tessari G, Girolomoni G. Nonmelanoma skin cancer in solid organ transplant recipients: update on epidemiology, risk factors, and management. Dermatol Surg 2012;38:1622-30.
6. Zwald FO, Christenson LJ, Billingsley EM, Zeitouni NC, Ratner D, Bordeaux J et al.; Melanoma Working Group of The International Transplant Skin Cancer Collaborative and Skin Care in Organ Transplant Patients, Europe. Melanoma in solid organ transplant recipients. Am J Transplant 2010;10:1297-304.
7. Penn I. Malignant melanoma in organ allograft recipients. Transplantation 1996;61:274-8.
8. Belloni-Fortina A, Piaserico S, Bordignon M, Gambato M, Senzolo M, Russo FP et al. Skin cancer and other cutaneous disorders in liver transplant recipients. Acta Derm Venereol 2012;92:411-5.
9. Berg D, Otley CC. Skin cancer in organ transplant recipients: Epidemiology, pathogenesis, and management. J Am Acad Dermatol 2002; 47:1-17; quiz 18-20.
10. Alaibac M, Piaserico S, Rossi CR, Foletto M, Zacchello G, Carli P et al. Eruptive melanocyte nevi in patients with renal allografts. J Am Acad Dermatol 2003;49:1020-2.
11. Grob JJ, Bastuji-Garin S, Vaillant L, Roujeau JC, Bernard P, Sas-solas B et al. Excess of nevi related to immunodeficiency: a study in HIV-infected patients and renal transplant recipients. J Invest Dermatol 1996;107:694-7.
12. Naldi L, Adamoli L, Fraschini D, Corbetta A, Imberti L, Reseghetti A et al. Number and distribution of melanocyte nevi in individuals with a history of childhood leukemia. Cancer 1996;77:1402-8.
13. Hughes B, Cunliffe W, Bailey C. Excess benign melanocyte naevi in children after chemotherapy for malignancy. Br Med J 1989;299:88-91.
14. Bovenschen HJ, Tjioe M, Vermaat H, de Hoop D, Witteman BM, Janssens RW et al. Induction of eruptive benign melanocyte naevi by immune suppressive agents, including biologicals. Br J Dermatol 2006;154:880-4.
15. Zattra E, Fortina AB, Alaibac M. Excess of melanocyte nevi in a patient treated with natalizumab for multiple sclerosis. Eur J Dermatol 2012;22:416-7.
16. Smith CH, McGregor JM, Barker JN, Morris RW, Rigden SP, Mac-Donald DM. Excess melanocytic nevi in children with renal allografts. J Am Acad Dermatol 1993;28:51-5.
17. Barker JN, MacDonald DM. Eruptive dysplastic naevi following renal transplantation. Clin Exp Dermatol 1988;13:123-5.
18. Zattra E, Belloni-Fortina A, Bordignon M, Piaserico S, Alaibac M. Immunosuppression and melanocyte proliferation. Melanoma Res 2009;19:63-8.
19. Duvic M, Lowe L, Rapini RP, Rodriguez S, Levy ML. Eruptive dysplastic eruptive dysplastic nevi associated with human immunodeficiency virus infection. Arch Dermatol 1989; 125, 397-401.
20. Kittler H, Seltenheim M, Dawid M, Pehamberger H, Wolff K, Binder M. Frequency and characteristics of enlarging common melanocytic nevi. Arch Dermatol 2000;136:316-20.
21. Steiner A, Pehamberger H, Binder M, Wolff K. Pigmented Spitz nevi: improvement of the diagnostic accuracy by epiluminescence microscopy. J Am Acad Dermatol 1992;27:697-701.
22. Daniel V, Naujokat C, Sadeghi M, Wiesel M, Hergesell O, Opelz G. Association of circulating interleukin (IL)-12-and IL-10-producing dendritic cells with time posttransplant, dose of immunosuppression, and plasma cytokines in renal-transplant recipients. Transplantation 2005;15;79:1498-506.
23. Barten MJ, Garbade J, Bittner HB, Fiedler M, Dhein S, Thiery J et al. Effects of immunosuppression on circulating dendritic cells: an adjunct to therapeutic drug monitoring after heart transplantation. Int Immunopharmacol 2006;20:2011-7.
24. Vance K, Goding CR. The transcription network regulating melanocyte development and melanoma. Pigment Cell Res 20O4;17:318-25.
25. Goding CR. Mitf from neural crest to melanoma: signal transduction and transcription in the melanocyte lineage. Genes Dev 2000;15:1712-28.
26. Piaserico S, Alaibac M, Fortina AB, Peserico A. Clinical and derma-toscopic fading of post-transplant eruptive melanocytic nevi after suspension of immunosuppressive therapy. J Am Acad Dermatol 2006;54:338-40.
27. Zonta E, Brumana MB, Montin A, Piaserico S, Belloni-Fortina A, Alaibac M. Rejection-mediated regression of melanocytic naevi in an immunosuppressed organ transplant recipient. Acta Derm Vener-eol 2014 [Epub ahead of print].
28. Belloni-Fortina A, Piaserico S, Tonin E, Alaibac M. Melanoma and immunosuppression. Dermatology 2009;218:88.
29. Marshall JA, Forster TH, Purdie DM, Lanagan CM, O'Connor LE, O'Rourke MG et al. Immunological characteristics correlating with clinical response to immunotherapy in patients with advanced metastatic melanoma. Immunol Cell Biol 2006;84:295-302.
30. Kubica AW1, Brewer JD. Mayo Clin Proc. Melanoma in immunosuppressed patients. 2012;87:991-1003.
31. Maio M. Melanoma as a model tumour for immuno-oncology. Ann Oncol 2012;23(Suppl 8):viiil0-4.
32. Wolchok JD, Saenger Y. The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation. Oncologist 2008;13(Suppl4):2-9.
33. Cebon J, Gedye C, John T, Davis ID. Immunotherapy of advanced or metastatic melanoma. Clin Adv Hematol Oncol 2007;5:994-1006.
34. McCarter MD, Baumgartner J, Escobar GA, Richter D, Lewis K, Robinson W et al. Immunosuppressive dendritic and regulatory T cells are upregulated in melanoma patients. Ann Surg Oncol 2007;14:2854-60.
35. Dinh QQ, Chong AH: Melanoma in organ transplant recipients: the old enemy finds a new battleground. Australasian J Dermatol 2007;48:199-207.
36. Lindelof B, Sigurgeirsson B, Gabel H, Stern RS: Incidence of skin cancer in 5, 356 patients following organ transplantation. Br J Dermatol 2000;143:513-9.
37. Bastiaannet E, Homan-van der Heide JJ, Ploeg RJ, Hoekstra HJ. No increase of melanoma after kidney transplantation in the northern part of the Netherlands. Melanoma Res 2007;6:349-53.
38. Le Mire L, Hollowood K, Gray D, Bordea C, Wojnarowska F. Melanomas in renal transplant recipients. Br J Dermatol 2006;154:472-7.
39. Matin RN, Mesher D, Proby CM, Bouwes Bavinck JN, del Marmol V et al. Skin care in organ transplant patients, Europe (SCOPE) group. Melanoma in organ transplant recipients: clinicopathological features and outcome in 100 cases. Am J Transplant 2O08;8:1891-900.
40. Brewer JD. Melanoma in immunosuppressed patients [editorial]. Exp Rev Dermatol 2010;5:247-50.
41. Garbe C, Buttner P, Weiss J, Soyer HP, Stocker U, Krüger S et al. Risk factors for developing cutaneous melanoma and criteria for identifying persons at risk: Multicentre case-control study of the Central Malignant Melanoma Registry of the German Dermatologi-cal Society. J Invest Dermatol 1994;102:695-9.
42. Greene MH. The prevention of cutaneous malignant melanoma: High risk groups, chemoprevention, education and screening. In: Nathanson L, editor. Current research and clinical management of melanoma. Boston: Kluwer; 1993. p. 103.
43. Brewer JD, Christenson LJ, Weaver AL, Dapprich DC, Weenig RH, Lim KK et al. Malignant melanoma in solid transplant recipients: collection of database cases and comparison with Surveillance, Epidemiology, and End Results data for outcome analysis. Arch Dermatol 2011; 147:790-6.
44. Dapprich DC, Weenig RH, Rohlinger AL, Weaver AL, Quan KK, Keeling JH et al. Outcomes of melanoma in recipients of solid organ transplant. J Am Acad Dermatol 2008;59:405-17.
45. Colegio OR, Proby CM, Bordeaux JS, McGregor JM; Melanoma Working Group of the International Transplant Skin Cancer Collaborative (ITSCC) & Skin Care in Organ Transplant Patients, Europe (SCOPE). Prognosis of pretransplant melanoma. Am J Transplant 2009;9:862.
46. Myron Kauffman H, McBride MA, Cherikh WS, Spain PC, Marks WH, Roza AM. Transplant tumor registry: donor related malignancies. Transplantation 2002;74:358-62.
47. Brewer JD, Christenson LJ, Weenig RH, Weaver AL. Effects of chronic lymphocytic leukemia on the development and progression of malignant melanoma. Dermatol Surg 2010;36:368-76.
48. Strauss DC, Thomas JM. Transmission of donor melanoma by organ transplantation. Lancet Oncol 2010; 11:790-6.
49. Milton CA1, Barbara J, Cooper J, Rao M, Russell C, Russ G. The transmission of donor-derived malignant melanoma to a renal allograft recipient. Clin Transplant 2006;20:547-50.
50. Mocellin S, Hoon D, Ambrosi A, Nitti D, Rossi CR. The prognostic value of circulating tumor cells in patients with melanoma: a systematic review and meta-analysis. Clin Cancer Res 2006; 12:4605-13.
51. Chen KT1, Olszanski A, Farma JM. Donor transmission of melanoma following renal transplant. Case Rep Transplant 2012;2012:764019.
52. Birkeland SA, Storm HH. Risk for tumor and other disease transmission by transplantation: a population-based study of unrecognized malignancies and other diseases in organ donors. Transplantation 2002;74:1409-13.
53. Stephens JK, Everson GT, Elliott CL, Kam I, Wachs M, Haney J et al. Fatal transfer of malignant melanoma from multiorgan donor to four allograft recipients. Transplantation 2000;70:232-6.
54. Milton CA, Barbara J, Cooper J, Rao M, Russell C, Russ G. The transmission of donor-derived malignant melanoma to a renal allograft recipient. Clin Transplant 2006;20:547-50.
55. Suranyi MG, Hogan PG, Falk MC, Axelsen RA, Rigby R, Hawley C et al. Advanced donor-origin melanoma in a renal transplant recipient: immunotherapy, cure, and retransplantation. Transplantation 1998;66:655-61.